Core Viewpoint - BeiGene (06160) announced a new subscription period for its 2018 Employee Stock Purchase Plan, which will run from March 2, 2026, to August 31, 2026, allowing eligible employees to purchase shares at a 15% discount from market price [1] Group 1 - The 2018 Employee Stock Purchase Plan allows eligible employees to buy shares, including American Depositary Shares, with funds deducted from their salaries earned during the subscription period [1] - The plan is managed by the company's Board Compensation Committee [1] - The company believes that providing employees with the opportunity to gain ownership through the Employee Stock Purchase Plan encourages continued employment and aligns employee interests with those of shareholders, benefiting both the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 誠如先前公告所述，於二零二四年，本公司與一家專注研發舒緩痛楚及神經痛症藥物之納 斯達克上市公司 Dogwood Therapeutics, Inc.（「Dogwood」）完成交易。本公司現時持有 Dogwood 之多數股權。於二零二五年，本公司將處於後期研發階段之黑色素瘤疫苗 seviprotimut-L出售予另一家納斯達克上市公司 TransCode Therapeutics, Inc.（「TransCode」） 以獲取其股權。 隨 著 本公司持有 Sequencio 、 TransCode 及 Dogwood ， 本公司 已建立 研發平台， 其多元化研發組合涵蓋早期及後期項目，聚焦於當前醫療需求尚未得到充分滿足之領域。 承董事會命 長江生命科技集團有限公司 公司秘書 （於開曼群島註冊成立之有限公司） （股份代號：0775） 就成立順譜醫藥科技有限公司 以全力推進治療性癌症疫苗研發之 自願性公告 長江 ...

Core Viewpoint - The article discusses the evolution and differentiation of CAR-T cell therapy, highlighting the challenges of autologous CAR-T and the emergence of allogeneic UCAR-T and in vivo CAR-T as key development directions in the industry [2][3][25]. Group 1: CAR-T Technology Development - Autologous CAR-T therapy has established clinical value but faces significant limitations such as long production cycles, high costs, and manufacturing failures [2][8]. - Allogeneic UCAR-T offers a solution to these challenges by using healthy donor cells, allowing for immediate availability, cost control, and enhanced safety [2][10]. - In vivo CAR-T, which generates CAR-T cells directly within the patient, is gaining attention for its potential to reduce treatment time and costs, although it is still in early exploration stages [3][9]. Group 2: Technical Pathways and Maturity - The CAR-T field has three distinct technical pathways: autologous CAR-T, in vivo CAR-T, and UCAR-T, each with unique advantages and limitations [6][7]. - Autologous CAR-T is commercially mature but has significant bottlenecks, while in vivo CAR-T is a hot topic but faces technical challenges and is still in early clinical exploration [8][9]. - UCAR-T is evolving through technological iterations, addressing early challenges such as immune rejection and storage issues, and is becoming a critical pathway in CAR-T development [10][13]. Group 3: UCAR-T's Technological Iteration - Early UCAR-T faced issues like immune rejection and short in vivo persistence, but advancements in gene editing technologies are overcoming these hurdles [14][15]. - Innovative strategies such as "disguise" and "counterattack" are being developed to enhance the persistence and efficacy of UCAR-T cells [15][16]. - The strategic knockout of HLA molecules is emerging as a key innovation to address immune rejection, significantly improving the clinical applicability of UCAR-T [16]. Group 4: Market Opportunities and Challenges - The field of autoimmune diseases presents a significant opportunity for UCAR-T, as it aligns well with the challenges of obtaining high-quality autologous T cells [17][19]. - Domestic companies are advancing UCAR-T therapies into clinical stages for autoimmune diseases, positioning themselves in a less competitive market compared to blood cancers [17][19]. - The safety and tolerability of UCAR-T in autoimmune patients are critical metrics for assessing its maturity and potential market success [20][21]. Group 5: Future Outlook and Value Proposition - The coexistence of autologous CAR-T, UCAR-T, and in vivo CAR-T reflects a layered approach to meet diverse clinical needs, with UCAR-T focusing on accessibility and standardization [23][25]. - 2026 is anticipated to be a pivotal year for validating the clinical value of UCAR-T, with several companies expected to release important clinical data [23][25]. - The balance of safety, durability, and accessibility will be central to the competitive landscape of CAR-T therapies, with UCAR-T providing a clearer risk-reward structure [25][26].

Investment Rating - The report suggests a positive investment outlook for the targeted protein degradation (TPD) industry, indicating it is at a historical turning point for commercialization, with significant growth potential similar to the ADC sector [1]. Core Insights - The TPD field is transitioning from a scientific concept to a commercial explosion, with key catalysts expected in 2026, including the approval of Arvinas' ARV-471 and BMS's Iberdomide, marking the realization of TPD technology's value after over 20 years of development [1]. - The report highlights the dual-driven technological landscape of PROTAC and molecular glue, with rapid penetration into new therapeutic areas such as autoimmune diseases, showcasing the industry's adaptability and growth potential [2]. - The emergence of AI technologies is accelerating the drug development process in TPD, making this an optimal time for investment as the first PROTAC molecules are set to commercialize [17]. Summary by Sections Investment Logic - TPD is expected to replicate the growth trajectory of ADCs, overcoming barriers associated with traditional small molecule inhibitors by utilizing the UPS and ALPS systems for effective protein degradation [1]. - 2026 is projected to be a pivotal year for commercialization, with significant drug approvals anticipated [1]. Technological Pathways - The report outlines a dual-driven approach with PROTAC and molecular glue technologies, emphasizing their clinical validation and the potential for new therapeutic applications [2]. - The self-immune field is highlighted as a strategic growth area, with companies like Kymera and Monte Rosa developing promising candidates [2]. Competitive Landscape - Key catalysts in 2026 are expected to reshape the competitive landscape, with companies demonstrating platform capabilities and differentiated target strategies likely to enjoy valuation premiums [3]. - The report identifies several leading companies and their promising pipelines, including Arvinas, Nurix, and Monte Rosa, which are positioned to capitalize on upcoming clinical data and market opportunities [3]. Investment Recommendations - The report recommends focusing on late-stage assets nearing commercialization, particularly those from Arvinas and BMS, while also highlighting biotech firms like Monte Rosa and Kymera that are expanding into autoimmune and chronic disease markets [4].

Financial Performance - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, $5.6 million from global EAP reimbursements, and $1.8 million from royalties under the AZSTARYS license [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, $800,000 from OLPRUVA, $13 million from global EAP reimbursements, and $5 million from royalties [24] - Operating expenses for Q4 were $23 million, a decrease of $1.5 million year-over-year, while full-year operating expenses were $90.4 million, down $6.6 million from 2024 [22][24] - Net income for Q4 was $12.2 million, compared to a net loss of $35.7 million in Q4 2024, and full-year net income was $83.2 million, compared to a net loss of $105.5 million in 2024 [23][24] Business Line Performance - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with strong commercial performance reflected in 52 prescription enrollment forms received in the first year of commercialization [5][6] - In Q4, 24 new prescription enrollment forms were received, contributing to a total of 161 enrollments since launch [6][14] - The company is expanding access to MIPLYFFA through a global expanded access program, with 113 patients enrolled by the end of 2025 [8] Market Data - The estimated U.S. prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7] - In Europe, NPC prevalence is estimated at around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] - Diagnosis rates in Europe are higher due to the approval of miglustat, leading to stronger physician awareness and higher patient identification [10] Company Strategy and Industry Competition - The company aims to redefine therapies for rare diseases, focusing on patient-centricity, integrity, accountability, innovation, and courage [5] - MIPLYFFA has exclusivity in the U.S. through 2031 under the Orphan Drug Designation, and the company is pursuing a patent term extension [7] - The company is also advancing celiprolol for the treatment of vascular Ehlers-Danlos syndrome, with ongoing Phase III studies [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by both previously diagnosed and newly diagnosed patients [15][16] - The company is focused on expanding access and strengthening relationships with key opinion leaders to maximize commercial impact [10] - Management highlighted the importance of ongoing education and awareness campaigns to facilitate early diagnosis and treatment [16][18] Other Important Information - The company moved its headquarters to Boston to enhance collaboration and access to specialized talent [12][13] - The new CFO, Justin Renz, officially started on the call date and will support the company's long-term value creation [4][28] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [33][34] Question: What is the expected timeline for diagnosis confirmation? - Management indicated that the timeline for diagnosis can vary significantly due to the nature of rare diseases, but efforts are being made to streamline the process [37][40] Question: Can you discuss persistency rates for patients on therapy? - Management stated that it is too early to provide meaningful data on persistency but expressed encouragement from refill rates observed [45][46] Question: How is the initial experience with the Uniphar collaboration? - Management expressed satisfaction with the collaboration, noting that it has facilitated rapid product delivery to patients [47][48] Question: What is the expected growth of EAP revenue? - Management clarified that EAP revenue is based on individual patient shipments and will have variability quarter-over-quarter [54][55] Question: How is the gross to net evolving in the U.S.? - Management noted that gross to net has evolved and is dynamic, making it difficult to provide specific guidance [58] Question: What is the average age of patients on MIPLYFFA? - Management indicated that approximately half of MIPLYFFA patients are adults, reflecting the patient mix seen in the expanded access program [64][66] Question: What are the next steps for the EMA application? - Management confirmed readiness to respond to the EMA's questions and emphasized the robustness of the data package submitted [69]

Core Insights - NovaBridge Biosciences is conducting a business update call to discuss the clinical data and development plan for its pipeline asset VIS-101 [2][3] Group 1: Company Overview - NovaBridge operates under a hub-and-spoke business model, with the first spoke company being Visara, which focuses on ophthalmology [3] Group 2: Clinical Data and Development Plan - The presentation will include details on the Phase IIa clinical data for VIS-101, the first pipeline asset of Visara [3] - The company will also provide insights from key opinion leaders (KOLs) regarding the clinical development plan for VIS-101 [3]

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx (NasdaqGS: IFRX) - **Focus**: Development of izicopan, a C5AR molecule inhibitor, for various immunological conditions, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Key Points Drug Development and Pipeline - **Izicopan**: Positioned as a best-in-class potential drug targeting the complement terminal pathway, which is significant in various immunological diseases [1] - **Clinical Trials**: Completed a Phase 2a trial for izicopan in HS and CSU, with promising early efficacy signals [2][5] - **Regulatory Discussions**: Ongoing discussions with the FDA regarding the regulatory path and potential new endpoints for clinical trials [2][13] Efficacy Data - **HS Data**: The drug showed a significant reduction in lesions and draining tunnels, with 50% of patients in the high-dose group free of draining tunnels after four weeks [7][8] - **Pain Reduction**: Notable pain reduction was reported across all dosing groups, which is a critical factor for patient quality of life [5][8] - **HiSCR Endpoint Issues**: The current HiSCR endpoint has shown variability in placebo responses, complicating trial outcomes. A modified HiSCR endpoint is being discussed with the FDA [12][22] Market Opportunities - **ANCA Vasculitis**: InflaRx is exploring opportunities in ANCA vasculitis, a serious condition with significant unmet medical needs [3][34] - **Avacopan Market Dynamics**: The potential withdrawal of avacopan from the market due to safety concerns presents an opportunity for izicopan, which does not share the same liver toxicity issues [36][41] Financial Position and Strategy - **Funding**: The company is funded into mid-2027 and is exploring collaborations with pharmaceutical companies to expand the potential applications of izicopan [32][33] - **Capital Markets Day**: An upcoming event is expected to provide clarity on the development path for HS and other indications, as well as potential collaborations [30] Future Directions - **Exploratory Studies**: Initiating PK bridging studies in China to facilitate faster and more cost-effective data generation for different indications [59][60] - **Focus on CSU**: Despite mixed results in CSU, there is a belief in the drug's potential, particularly in severe cases, and plans to further explore this indication as funding allows [56] Additional Insights - **Regulatory Challenges**: The company acknowledges the complexities of trial design and the need for larger patient cohorts to achieve statistically significant results [20][22] - **Collaborative Efforts**: Engaging with other companies to explore alternative indications and enhance the drug's market potential [58] This summary encapsulates the critical aspects of InflaRx's current status, drug development efforts, market opportunities, and strategic direction as discussed in the conference call.

Neurocrine Biosciences Conference Call Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date**: March 09, 2026 - **Key Products**: INGREZZA and CRENESSITY Core Industry Insights - **Market Position**: Neurocrine has two approved products, INGREZZA and CRENESSITY, with a revenue guidance of $2.7 billion to $2.8 billion for INGREZZA in 2026, reflecting significant growth potential [8][11] - **Sales Force Expansion**: A recent expansion of the sales force is expected to enhance patient outreach and support for tardive dyskinesia treatment [8][10] Product Performance - **INGREZZA**: - Launched 9 years ago, still experiencing double-digit growth [8] - Expected to achieve nearly 10% growth in 2026, with volume growth projected at 14%-15% after accounting for price declines [61] - Currently, only 10% of the 800,000 patients with tardive dyskinesia are on VMAT2 inhibitors, indicating substantial market potential [61] - **CRENESSITY**: - First new treatment for congenital adrenal hyperplasia (CAH) in over 70 years, generating over $300 million in sales in its first year [9] - Targeting a patient population of approximately 20,000 with classic CAH, with an additional 60,000 to 80,000 with non-classic CAH [17] - The launch is considered one of the top 10% of rare disease launches historically [9] Financial Health - **Cash Position**: Neurocrine holds over $2.5 billion in cash with no debt, indicating strong financial stability [11] - **R&D Investment**: The company allocates around 35% of its revenue back into research and development, supporting a robust pipeline [10][86] Growth Strategies - **Patient Acquisition**: - Less than 50% of the initial 2,000 patients for CRENESSITY came from Centers of Excellence, indicating room for growth in this area [20] - The company is optimistic about increasing patient access through ongoing efforts and clinician engagement [20][28] - **Reimbursement Success**: - Over 80% of prescriptions for CRENESSITY are being reimbursed, with a strong foundation laid for reimbursement processes prior to launch [30][28] - The reimbursement landscape is favorable, with a manageable process for obtaining authorizations [28] Future Prospects - **Clinical Trials**: Two late-stage Phase 3 trials are underway, focusing on schizophrenia and depression, with results expected in 2027 and 2028 [10] - **Obesity Market Entry**: Neurocrine is exploring opportunities in the obesity space, leveraging its existing expertise and planning to initiate trials soon [86][82] Key Challenges - **Market Competition**: The company acknowledges the competitive landscape in obesity and is focused on differentiating its offerings [85] - **Investment Scrutiny**: There are concerns regarding high spending levels, but the company emphasizes long-term growth over short-term profitability [87][89] Conclusion Neurocrine Biosciences is positioned for significant growth with its innovative products and strong financial foundation. The company is actively expanding its market presence while investing in research and development to sustain its pipeline and address unmet medical needs.

Core Viewpoint - In the past year, Innovent Biologics has achieved breakthroughs in multiple disease areas, marking significant advancements in the biopharmaceutical industry in China [1] Group 1: Product Developments - The launch of Tislelizumab (替妥尤单抗 N01) fills a 70-year gap in the treatment of thyroid eye disease in China [1] - Ma Shidu Peptide (玛仕度肽) is recognized as the world's first approved GCG/GLP-1 dual-target weight loss and blood sugar-lowering drug, showcasing the impact of domestic innovative drugs in global academic circles [1] Group 2: Market and Regulatory Environment - Continuous reforms in drug regulation, medical insurance, and capital markets have facilitated the rapid translation of research outcomes into patient benefits [1] Group 3: Strategic Direction - Positioned at the new starting point of the 14th Five-Year Plan, Innovent Biologics aims to enhance its independent R&D capabilities and adhere to a strategy of "innovation as the cornerstone and globalization" [1] - The company plans to deepen domestic and international collaborations to steadily advance towards becoming a world-class biopharmaceutical company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 本集團產品德谷胰島素注射液獲批上市 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 德谷胰島素是新一代超長效基礎胰島素類似物，用于成人糖尿病的治療，可單獨使用 或與口服降糖藥、餐時胰島素聯合用藥，全面滿足臨床長期血糖管理需求。每日一次 皮下注射，具有超長平穩控糖、安全性高、給藥時間靈活等特點。現時，德谷胰島素 已納入國家醫保目錄（二零二五年版）乙類藥品，可及性與經濟性優勢顯著。 本次獲批是本公司在糖尿病領域實現關鍵技術突破的又一重要成果。未來，本公司將 持續致力於新產品研發，並重點提升在生物醫藥行業的競爭力及創造力，深耕慢病治 療領域，以更優質的產品、更完善的管線服務臨床、惠及患者，預期將為本公司及 ...